Therapy News and Research

RSS

New technique to deliver cancer treatments directly to certain tumours

Research conducted and patented by Dr Mark Howard at the University of Kent's School of Biosciences has led to the development of a new technique that will deliver cancer treatments directly to certain tumours.

26 Mar 2010

Single-incision laparoscopy reduces postoperative complications

Surgeons at the University of California, San Diego School of Medicine report what is believed to be the nation's first single-incision laparoscopy to perform a combined colectomy and kidney-preserving therapy.

26 Mar 2010

New gateway may be lifesaver for patients with AML: Study

Canadian researchers have discovered a previously hidden channel to attack leukemia and other cancer cells, according to a new study published in the Journal of Biological Chemistry. The findings from the Universit- de Montr-al, Maisonneuve-Rosemont Hospital and Universit- Laval may change the way doctors treat cancer patients.

26 Mar 2010

Novelos Therapeutics commences enrollment in Phase 2 trial of NOV-205 for chronic hepatitis C

Novelos Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that it has enrolled the first patient in a U.S. Phase 2 trial evaluating NOV-205 as monotherapy in up to 40 chronic hepatitis C genotype 1 patients who previously failed treatment with pegylated interferon plus ribavirin.

26 Mar 2010

Standard HCV therapy less effective in urban minority patients: Study

A recent study confirms that the standard hepatitis C therapy, pegylated interferon and ribavirin, is significantly less effective in urban minority patients treated in an ordinary clinical practice setting compared with results produced during clinical trials.

26 Mar 2010

AVASTIN receives Health Canada approval for patients with GBM

Roche Canada announced today that Health Canada has approved AVASTIN(R) (bevacizumab), as a single agent, for the treatment of patients with glioblastoma multiforme, the most aggressive primary malignant brain tumour, after relapse or disease progression, following prior therapy.

26 Mar 2010

Aastrom Biosciences' RESTORE-CLI trial: Final patient treated

Aastrom Biosciences, Inc., a leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today reported that the final patient has been treated in the company's ongoing multi-center, randomized, double-blind, placebo-controlled U.S. Phase 2b clinical trial designated RESTORE-CLI. This patient received intramuscular injections of either Aastrom's tissue repair cells (TRCs) or electrolyte solution (placebo) for the treatment of critical limb ischemia (CLI), the end-stage of peripheral arterial disease.

26 Mar 2010

EVMS researchers awarded $1,076,250 grant to develop functional cure for Type 1 diabetes

Researchers at the Eastern Virginia Medical School Strelitz Diabetes Center have been awarded a $1,076,250 grant by the Department of Defense Peer Reviewed Medical Research Program to develop new ways of reversing the underlying causes of Type 1 diabetes.

26 Mar 2010

Medicare Roundup: Changes from health reform, payments for HIV patients

USA Today: "Perhaps the biggest factor in whether your Medicare costs will rise or fall depends on your Medicare plan. There are two: a traditional Medicare plan run by the federal government and Medicare Advantage, which is run by private insurance companies. Medicare Advantage costs more than the traditional plan, but provides more generous benefits.

26 Mar 2010

Beaumont Hospital opens women's urology center

It’s something that women don’t talk about even to their best friends or their doctors. That’s why Beaumont Hospitals has created a new Women’s Urology Center offering leading-edge treatments, innovative research and the most advanced minimally invasive procedures for women’s urological conditions such as incontinence, pelvic pain and sexual dysfunction.

25 Mar 2010

New therapies increase survival rates in post-transplant liver cancer patients

A recent study found that sirolimus-based immunosuppression following liver transplantation in patients with non-resectable hepatocellular carcinoma (liver cancer) significantly increases survival rates for this patient population. Results of this study appear in the April issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases (AASLD).

25 Mar 2010

Hepatitis C treatment less effective in urban minority patients

A recent study confirms that the standard hepatitis C (HCV) therapy, pegylated interferon and ribavirin, is significantly less effective in urban minority patients treated in an ordinary clinical practice setting compared with results produced during clinical trials. Results of this study appear in the April issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.

25 Mar 2010

ASCO, ESMO and OECI endorse WIN Symposium's initiatives on improving outcomes of cancer

The WIN Consortium, supported by its media partner Nature Publishing Group, has opened registration for the second annual WIN Symposium, to be held in the Palais des Congrès, Paris, on the 7th to 9th of July 2010. The WIN Symposium is an open and interactive forum designed to promote rapid translation of ground-breaking personalized cancer medicine discoveries to clinical practice.

25 Mar 2010

Genetic variation associated with lower risk of sudden cardiac arrest:Study

Physician-scientists at the Cedars-Sinai Heart Institute have found that a genetic variation is associated with lower risk of sudden cardiac arrest, a disorder that gives little warning and is fatal in about 95 percent of cases. Findings will be published tomorrow by the Public Library of Science (PloS One).

25 Mar 2010

BeaconEquity.com announces investment report on AEterna Zentaris

BeaconEquity.com announces an investment report featuring AEterna Zentaris Inc. (Nasdaq:AEZS). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

25 Mar 2010

Innovation holds the key for solving healthcare's dilemmas, says Eli Lilly

In an address to the American Chamber of Commerce in Germany today, John C. Lechleiter, Ph.D., chairman, president and chief executive officer of Eli Lilly and Company, said that innovation holds the key to solving one of healthcare's thorniest dilemmas: how to improve quality and access while controlling costs.

25 Mar 2010

Health care reform bill includes provisions for MTM programs, says Arcadia Resources

Arcadia Resources, Inc., a leading provider of innovative consumer health care services under the Arcadia HealthCare(SM) and DailyMed Pharmacy program, today announced the healthcare reform bill advanced in the U.S. House of Representatives on March 21st contains important provisions related to medication therapy management (MTM) including a series of grant and pilot programs.

25 Mar 2010

Biogen Idec and Elan begin comparative trial of MS treatments

Biogen Idec and Elan Corporation, plc (NYSE: ELN) today announced enrollment of the first patient in a global Phase IIIb, randomized, rater-blinded, active-controlled study designed to evaluate switching to TYSABRI® (natalizumab) from Copaxone® (glatiramer acetate) or Rebif® (interferon beta-1a) in patients with relapsing remitting multiple sclerosis.

25 Mar 2010

New ultrasound device shows promising results for treating joint and muscle pain

It's lightweight, smaller than most iPods and can deliver low-intensity ultrasound therapy for up to 10 hours. It just might revolutionize pain relief - and save patients time.

25 Mar 2010

EMA accepts MAA filing of ViroPharma's Cinryze for HAE

ViroPharma Incorporated today announced that the European Medicines Agency (EMA) has accepted the filing of its Marketing Authorization Application for Cinryze for acute treatment and prophylaxis against hereditary angioedema, which was submitted through the centralized procedure in March 2010. ViroPharma is seeking European approval for both prevention and treatment of acute attacks of hereditary angioedema.

25 Mar 2010